Evidence map›Paper›PMID 31144104›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2019

Neuropsychiatric aspects of Parkinson's disease.

Anna Nagy, Anette Schrag

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Progress of Immunotherapies in Parkinson's Disease.CNS neuroscience & therapeutics · 2026
    Review
  3. Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Compound impact of cognitive and physical decline: A qualitative interview study of people with Parkinson's and cognitive impairment, caregivers and professionals.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Exploring Treatment for Depression in Parkinson's Patients: A Cross-Sectional Analysis.International journal of environmental research and public health · 2021
    Article
  18. NaJournal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna NagyDepartment of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, NW3 2PF, UK.
Anette SchragDepartment of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, NW3 2PF, UK. a.schrag@ucl.ac.uk.ORCID 0000-0002-9872-6680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout the natural history of Parkinson's Disease (PD), from the pre-diagnostic phase to end stage disease, neuropsychiatric manifestations represent a core feature of the disease. This review summarises current knowledge on the features of depression, anxiety, apathy, fatigue, impulse control disorders (ICDs) and psychosis in PD. These co-morbidities are common and still frequently under-recognised. Their impact on quality of life is considerable, with depression having been shown to be the main determinant of health-related quality of life in PD patients. As well as formal diagnostic criteria, multiple scales have been developed to allow for assessment of these symptoms in both the clinic and research settings. The evidence base for treatment is variable, with increasing evidence for pharmacological and non-pharmacological treatment options for depression, but less robust evidence for the treatment of other neuropsychiatric features. Imaging studies are increasingly providing insight into the neural basis of these symptoms, with the hope that this insight will translate into treatments that can benefit patients.

Indexed as

HumansMental DisordersParkinson DiseasePrevalenceRisk FactorsAnxietyApathyDepressionImpulse control disordersNeuropsychiatric symptomsNon-motor symptomsParkinson’s diseasePsychosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.